CrystalGenomics Participates in JPM and Biotech Showcase

CrystalGenomics logo (Photo by CrystalGenomics)

[Asia Economy Reporter Lee Chun-hee] CrystalGenomics announced on the 22nd that it will participate in the '2023 JP Morgan Healthcare Conference' and 'Biotech Showcase' held next month to introduce its research and development status.

The JP Morgan Healthcare Conference will be held for four days from the 9th to the 12th of next month (local time) in San Francisco, USA. Every January, it is the largest event in the pharmaceutical and bio industry where healthcare companies and institutional investors from around the world gather. The Biotech Showcase, held in San Francisco during a similar period from the 9th to the 11th, is a large-scale biotech investment conference conducted annually by Demi Colton, a pharmaceutical and bio industry event company, and the EBD Group, which hosts the Bio Partnering Forum.

CrystalGenomics plans to introduce the US clinical development of ‘Ivaltinostat,’ a new drug candidate for cancer and anti-fibrosis treatment, through one-on-one partnering meetings with overseas bio companies and seek license-out and license-in partners.

A CrystalGenomics official said, "We plan to promote strategic alliances by introducing our innovative new drug development pipeline and US-centered clinical trials."

This content was produced with the assistance of AI translation services.